Similar rates of spontaneous clearance and SVR to treatment in reinfected patients vs those with initial HCV infection among HIV-infected individuals.
Mild to moderate injection-site reactions were observed with both agents but were tolerable and self-limiting.
Greater efficacy observed with tenofovir/emtricitabine vs abacavir/lamivudine, and for integrase inhibitors and vs NNRTIs as third drug.
Nearly 5-fold increased risk of hip fracture and 75% increased risk of all clinical fractures among HIV-infected patients in large Spanish public healthcare system cohort.
In a phase III, 48-week study, the reduced efavirenz dose achieved noninferior rates of HIV-1 RNA < 200 copies/mL and appeared to be associated with a slightly lower frequency of treatment-related adverse events.
Despite lack of access to viral load and genotypic resistance tests, use of recycled NRTIs in second-line lopinavir/ritonavir-based ART proved effective for disease control.
At primary endpoint, virologic suppression was achieved by 71% of patients treated with dolutegravir vs 64% treated with raltegravir, each with an optimized background regimen, with similar safety and tolerability.
NRTI-containing regimen associated with significantly greater loss of proximal femur and lumbar spine BMD loss at Week 48 in patients who had experienced virologic failure on a first-line NNRTI-based regimen.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.